# TandemAI

> TandemAI combines AI-driven molecular design, physics-based simulation and in-house chemistry and biology labs in a browser-based workspace called TandemViz. Founded in 2021, the company serves pharmaceutical, biotechnology and academic discovery teams through research services and software licenses, with an expanded peptide platform following its merger with Perpetual Medicines.

- **Founded:** 2021
- **Headquarters:** New York, United States
- **Founders:** Jeff He (Co-founder and CEO), Lanny Sun (Co-founder and Executive Chairman)
- **Products:** TandemViz, TandemFEP, TandemGen, TandemDock, TandemDynamics
- **Notable:** Launched TandemViz 1.0 in March 2023., Announced $82 million across three financing rounds through November 2025., Reported partnerships with four of the world’s top ten multinational pharmaceutical companies in November 2025.

## Products & services

- **TandemViz** — Browser-based platform connecting computational modules, molecular visualization, project data and wet-lab workflows; version 1.0 launched in March 2023.
- **TandemFEP** — Free-energy perturbation workflow for predicting relative binding affinity and guiding hit-to-lead and lead optimization.
- **TandemGen** — Generative molecular design integrated with screening and affinity prediction workflows.
- **TandemDock** — Docking tools for predicting ligand binding poses and supporting virtual screening.
- **TandemDynamics** — Molecular dynamics simulation and analysis tools.
- **TandemQueue** — Live synthesis queue with compound status, notes and prioritization.
- **TandemSandbox** — Collaborative structure-based molecular design workspace.
- **TandemAnalytics / LeadRL** — Analysis tools including LeadRL, which uses FEP-derived data, generative AI and reinforcement learning to suggest small-molecule analogues.
- **Medicinal chemistry and synthesis** — FTE-based synthetic chemistry, medicinal chemistry, purification, analytical support and discovery process research.
- **Biological assays** — Biochemical, cellular, biophysical and ADME profiling services for experimental validation.
- **Peptide discovery platform** — Computational design and synthesis capabilities expanded through the merger with Perpetual Medicines announced in July 2025.

## Achievements

- Launched TandemViz 1.0 in March 2023.
- Announced $82 million across three financing rounds through November 2025.
- Reported partnerships with four of the world’s top ten multinational pharmaceutical companies in November 2025.
- Perpetual Medicines and Third Rock Ventures reported a development candidate delivered in under 18 months in June 2026.

## Latest updates

- **2026-09** — TandemViz v3.12 release notes include CDD Vault integration; the company newsletter lists v3.12.19 dated September 30, 2026.
- **2026-06** — Perpetual Medicines and Third Rock Ventures announced a development candidate delivered in under 18 months and a milestone payment.
- **2026-05** — Mila announced its TandemAI research partnership focused on AI drug discovery and world models.
- **2025-11** — Closed a $22 million Series A extension and introduced LeadRL.

## Links

- Website: https://tandemai.com/
- LinkedIn: https://www.linkedin.com/company/tandemai/
- Twitter/X: https://twitter.com/TandemAI_
- GitHub: https://github.com/tandemai-inc

---

Profile page: https://yespress.io/tandemai
Published by YesPress — https://yespress.io
Last updated: 2026-10-03